Helixmith Co

Helixmith Co Gross Margin

The Gross Margin of Helixmith Co (084990.KQ) as of Oct 21, 2026 is 38.04 %. In the previous year, Gross Margin was 57.91 % — a change of -34.31% (lower).

Gross Margin

38.04 %

YoY

-34.31%

Last updated:

Gross Margin of Helixmith Co is 2025 38.04 % . Gross Margin of Helixmith Co was 2024 57.91 % . It decreases by -34.31% lower compared to the previous year.

For Helixmith Co, the gross margin of 38.0% is down versus 46.6% a few years ago.

The Helixmith Co Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
80.44 KRW
Jan 1, 2019
0.54 KRW
Jan 1, 2020
64.24 KRW
Jan 1, 2021
46.56 KRW
Jan 1, 2022
14.87 KRW
Jan 1, 2023
50.50 KRW
Jan 1, 2024
57.91 KRW
Jan 1, 2025
38.04 KRW
The Helixmith Co Gross Margin history
YEARGross MarginYoY
38.04 %-34.31%
57.91 %+14.68%
50.50 %+239.61%
14.87 %-68.06%
46.56 %-27.53%
64.24 %+11,851.84%
0.54 %-99.33%
80.44 %-1.85%
81.96 %-10.97%
92.06 %+0.39%
91.70 %+1.33%
90.50 %+9,943.95%
0.90 %+15.65%
0.78 %-0.27%
0.78 %+8.96%
0.72 %+132.61%
0.31 %+82.11%
0.17 %-3.97%
0.18 %-28.63%
0.25 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Helixmith Co Stock analysis

What does Helixmith Co do? Helixmith Co., Ltd. generates revenue through its Natural Products Business segment, which develops and sells raw materials for functional materials and health functional foods under brands like Alex, Murphine, and Nimosin. The New Biopharmaceutical Business segment focuses on developing treatments for diabetic neuropathy, diabetic ischemic foot ulcer, amyotrophic lateral sclerosis, ischemic heart disease, and anticancer therapies. Customers include companies in the health and pharmaceutical sectors seeking natural ingredients and specialized medical treatments. The company serves two distinct market segments: one for natural product raw materials and another for advanced biopharmaceutical solutions. The Natural Products Business segment targets clients requiring raw materials for functional materials and health functional foods, leveraging branded products Alex, Murphine, and Nimosin. The New Biopharmaceutical Business segment caters to healthcare providers and pharmaceutical firms developing treatments for specific medical conditions, including diabetic neuropathy, diabetic ischemic foot ulcer, amyotrophic lateral sclerosis, ischemic heart disease, and anticancer applications. Both segments operate within the broader health and biotechnology industries, with the company's revenue streams derived from product sales across these specialized markets. Helixmith Co., Ltd. monetizes its research and development efforts through the commercialization of natural substance-based raw materials and biopharmaceutical treatments. The company's product portfolio includes Alex, Murphine, and Nimosin for the natural products market, while its biopharmaceutical segment offers treatments for diabetic neuropathy, diabetic ischemic foot ulcer, amyotrophic lateral sclerosis, ischemic heart disease, and anticancer conditions. Revenue is generated from direct sales to businesses in the health, functional food, and pharmaceutical sectors, with no mention of additional revenue streams such as licensing or partnerships. Helixmith Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Helixmith Co stock

Gross Margin of Helixmith Co is 38.04 % in 2025.

Gross Margin of Helixmith Co changed from 57.91 % to 38.04 %, representing a -34.31% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Helixmith Co since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Helixmith Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Helixmith Co

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Helixmith Co